{"entity":{"id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","aka":[],"tldr":"German sarcoma specialist who was lead author of INTRIGUE, the trial that compared ripretinib with sunitinib as second-line treatment for GIST.","summary":"Sebastian Bauer leads the sarcoma programme at the West German Cancer Center in Essen. He was first author of the 2022 Journal of Clinical Oncology report of INTRIGUE, the phase 3 trial that found ripretinib was not superior to sunitinib in progression-free survival after imatinib in advanced gastrointestinal stromal tumour, though it was better tolerated. His laboratory studies resistance mechanisms in GIST.","asOf":"2026-09-18","links":[],"tags":["gist","sarcoma","trialist"],"related":[],"cancers":["gist-imatinib-resistant","gist","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["essen-wtz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-intrigue-ripretinib-vs-sunitinib-jco-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, West German Cancer Center, University Hospital Essen","institutionId":"essen-wtz","specialisms":["Gastrointestinal stromal tumour","Sarcoma","Kinase inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bauer%5BAuthor%5D"}],"papers":[]},"route":"/people/sebastian-bauer/","neighbours":{"cancer":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"},{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"institution":[{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/"}],"paper":[{"id":"paper-intrigue-ripretinib-vs-sunitinib-jco-2022","kind":"paper","name":"INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib","route":"/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/"}]}}